Edesa Biotech Shares Rise After Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
Edesa Biotech, Inc. (NASDAQ: EDSA) stock jumped more than 38% after the clinical-stage biopharmaceutical company announced positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a...